117 related articles for article (PubMed ID: 15377488)
21. [Radionuclide therapy for painful bone metastases].
Szefer J; Zuchora Z
Wiad Lek; 2004; 57(5-6):280-3. PubMed ID: 15518077
[TBL] [Abstract][Full Text] [Related]
22. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
23. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
24. Bony metastases seen on scintigraphy with samarium-153.
Verma N; Singh-Wadhwa S; Chan WL
Clin Nucl Med; 2002 Mar; 27(3):207. PubMed ID: 11852311
[No Abstract] [Full Text] [Related]
25. [Metabolic radiotherapy: what role will it have in 2001?].
George B; Douard MC; Rain JD
Cancer Radiother; 2002 May; 6(3):188-200. PubMed ID: 12116845
[TBL] [Abstract][Full Text] [Related]
26. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
27. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
[TBL] [Abstract][Full Text] [Related]
28. Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget's disease and rheumatoid arthritis.
Alberts AS; Brighton SW; Kempff P; Louw WK; Beek AV; Kritzinger V; Westerink HP; van Rensburg AJ
J Nucl Med; 1995 Aug; 36(8):1417-20. PubMed ID: 7543145
[TBL] [Abstract][Full Text] [Related]
29. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
Weiss K; Köck HH; Atefie K; Sinzinger H
Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421
[No Abstract] [Full Text] [Related]
30. Samarium-153 lexidronam for painful bone metastases.
Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
[No Abstract] [Full Text] [Related]
31. Pronounced therapeutic effect of samarium 153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma tibial tumor model.
Winderen M; Kjønniksen I; Fodstad O
J Natl Cancer Inst; 1995 Feb; 87(3):221-2. PubMed ID: 7707409
[No Abstract] [Full Text] [Related]
32. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Scher HI; Curley T; Yeh S; Tong W; O'Moore PV; Larson S
Adv Exp Med Biol; 1992; 324():115-29. PubMed ID: 1283494
[No Abstract] [Full Text] [Related]
33. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
Yousefnia H; Zolghadri S
Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
[TBL] [Abstract][Full Text] [Related]
34. 153Sm: its use in multiple myeloma and report of a clinical experience.
Abruzzese E; Iuliano F; Trawinska MM; Di Maio M
Expert Opin Investig Drugs; 2008 Sep; 17(9):1379-87. PubMed ID: 18694370
[TBL] [Abstract][Full Text] [Related]
35. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Goel A; Dispenzieri A; Geyer SM; Greiner S; Peng KW; Russell SJ
Blood; 2006 May; 107(10):4063-70. PubMed ID: 16424391
[TBL] [Abstract][Full Text] [Related]
36. Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.
Deilami-Nezhad L; Moghaddam-Banaem L; Sadeghi M
Appl Radiat Isot; 2017 Nov; 129():108-116. PubMed ID: 28843158
[TBL] [Abstract][Full Text] [Related]
37. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
Bruland OS; Skretting A; Solheim OP; Aas M
Acta Oncol; 1996; 35(3):381-4. PubMed ID: 8679270
[TBL] [Abstract][Full Text] [Related]
38. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
40. [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
Deng H; Tan T; Mo T; Zhong S; Kuan A; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):155-9. PubMed ID: 7490021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
